Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Arnulf Stenzl, Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore, Russell Zelig Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Ruslan Croitoru, Mingming Lian, Zhiqiang Xiao, Janet Kim, Matko Kalac, Yiyun Tang, Arun Azad
Institutions: University of Tübingen, Duke Cancer Institute, Yale University, Carolina Urologic Research Center, University of Chicago, University of Kansas Medical Center, Université de Lille, Hospital Clínic de Barcelona, P.A. Hertzen Moscow Oncology Research Institute, Kanazawa Medical University, Complexo Hospitalario Universitario A Coruña, Astellas Pharma (United States), Astellas Pharma (China), Pfizer (United States), Peter MacCallum Cancer Centre
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W7162485936
Cites:
Cited by:
Related to: